Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Job title: Full Professor of Computational Cardiology at Maastricht University
Personal History Prof Joost Lumens is a Full Professor of Computational Cardiology at Maastricht University. Academic History After completing a BSc in Biomedical Engineering, he obtained his MSc degree in Medical Engineering at the Eindhoven University of Technology (2005). He used the CircAdapt model to study the effect of ageing on left ventricular mechanics for his final MSc… View more
Author(s): Joost Daemen , Allen Jeremias , Ziad A Ali Added: 1 year ago
Join us for an informative video that explores the innovative approach of performing zero-contrast percutaneous coronary intervention (PCI) using advanced medical technologies and best practices. In recent years, contrast supply shortages and the need for improved patient outcomes have presented significant challenges in care delivery. In this video, our esteemed faculty will demonstrate the… View more
Author(s): Alexander van Rosendael , Dipti Itchhaporia Added: 6 months ago
In this episode of the "Innovations in Cardiology" series, host Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, Newport Beach, CA, US) is joined by Dr Alexander Van Rosendael (Leiden University Medical Center, Leiden, NL) to discuss the findings from the CONFIRM2 trial. Conducted from up to 50 international clinical CCTA sites with 35,000 patients, CONFIRM2 aims to improve comprehensive… View more
Author(s): Masahiro Natsuaki Added: 1 year ago
ESC 23 — Dr Masahiro Natsuaki (Saga University, JP) discusses the short and optimal duration of dual antiplatelet therapy-3 Study (STOPDAPT-3) (NCT04609111). In the STOPDAPT-2 study, 1-month dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy was shown to provide benefits in bleeding reduction over a 12-month period, however, other trials have shown high rates of bleeding at… View more
Author(s): Joo-Yong Hahn Added: 1 month ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel… View more